Table 3.
Consequences of staying on a failing regimen on viral genotype, at study enrolment, during the study, and at the end of the study (N=44)
| At time VF detecteda | ||||
|---|---|---|---|---|
|
|
||||
| Mutation | VF at enrolment (N=29) | Incident VF during study (N=15) | During studyb (N=44) |
End of studyc (N=44) |
| NRTI mutations | ||||
| M184V/I | 25 (86.2%) | 8 (53.3%) | +7 | 40 (90.9%) |
| Any TAMS | 14 (48.3%) | 0 | +20 | 28 (63.6%) |
| 1 TAM | 6 | 0 | 8 | |
| 2 TAMs | 5 | 0 | 11 | |
| ≥3 TAMS | 3 | 0 | 9 | |
| 69/Q151M | 2 (6.9%) | 0 | +5 | 7 (15.9%) |
| K65R/70E | 4 (13.8%) | 0 | +0 | 4 (9.1%) |
| TDF resistance | 6 (20.7%) | 0 | +9 | 15 (34.1%) |
| NNRTI mutations | ||||
| K103N | 7 (24.1%) | 2 (13.3%) | +3 | 12 (27.3%) |
| Y181C | 15 (51.7%) | 2 (13.3%) | +2 | 19 (43.2%) |
| G190A | 7 (24.1%) | 5 (33.3%) | +6 | 18 (40.9%) |
| K101E | 6 (20.7%) | 1 (6.7%) | +6 | 13 (29.5%) |
| ETR score>2.5 | 18 (62.1%) | 2 (13.3%) | +8 | 28 (63.6%) |
“At time VF detected” refers to mutations present in two sets of participants. Twenty-nine of the 44 participants who met criteria for VF only and no IF already had virologic failure at the time of enrolment in the study, when the first viral load was measured. Median time on therapy at enrolment for these participants was 25 months (VF at enrolment). Fifteen additional participants developed VF during the study period, meaning the first viral load measured during the study was suppressed but was detectable at a subsequent time point in the study (incident VF).
“During study column” refers to additional mutations accumulated during the study period among all 44 patients who met criteria for VF but not IF during the study.
“End of study column” refers to the presence of particular mutations on the last available genotype for all 44 patients who met criteria for VF but not IF during the study.